FDA grants breakthrough therapy designation to new drug candidate for FA cardiomyopathy
Lexeo Therapeutics, a New York City-based pharmaceutical company, has received the FDA’s breakthrough therapy designation for LX2006, its new drug candidate for treating Friedreich's ataxia (FA) cardiomyopathy.
The breakthrough therapy designation is designed to help companies accelerate the development and review of a new drug when early clinical evidence suggests it could represent a significant upgrade over available treatment options. LX2006 previously received the FDA’s fast track designation, a similar distinction that helps drugs gain approval faster when they appear to address an unmet need.
In addition, the FDA selected LX2006 to be part of its Chemistry, Manufacturing and Controls Development and Readiness Pilot (CDRP) program, yet another pathway for companies hoping to secure rapid approvals for new drug candidates.
“Receiving breakthrough therapy designation is a significant milestone, highlighting the potential of LX2006 and the strength of clinical evidence generated to date,” Sandi See Tai, MD, chief development officer of Lexeo Therapeutics, said in a statement. “We are highly encouraged by the impact of LX2006 on key measures of cardiac health, especially given the lack of treatments for FA cardiomyopathy today, which is the leading cause of death in FA. We are also optimistic about the improvements we have observed in functional measures of FA more broadly, and we look forward to a continued partnership with the FDA through the breakthrough therapy designation and the CDRP program as we work to bring this potential treatment to patients as quickly as possible.”
The FDA clearly sees significant potential in LX2006’s ability to help patients who present with FA cardiomyopathy. Its decisions are based largely on early data out of the SUNRISE-FA and CLARITY-FA clinical trials.
FA is a rare genetic disorder that impacts a person’s nervous system. Cardiomyopathy is a common symptom among patients presenting with FA.
There is currently no cure for FA, though a variety of treatments have been developed to manage specific symptoms. LX2006 works by delivering a functional frataxin gene to the patient, promoting frataxin expression and restoring mitochondrial function.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.